A Novel Scoring Framework to Analyze & Improve Access Pathways to Oral Oncology Therapies
Published Date: October 14, 2025
A Novel Scoring Framework to Analyze & Improve
Access Pathways to Oral Oncology Therapies
Written by Byrell Bautista, PharmDc, Megan Simonelli, PharmDc, Francheska Marte, PharmD, MBA, BCACP, Sophia Alfonso, PharmD, BCACP, & Kenneth Komorny, PharmD, BCPS
As more cancer care shifts toward oral therapies, “writing the prescription” is often the easy part. The harder part is getting the medication into a patient’s hands quickly, especially when limited distribution networks, prior authorizations, high out-of-pocket costs, and inconsistent support programs slow everything down. Those delays are not just frustrating. They can disrupt treatment timelines and add real stress for patients and care teams.
This article introduces a practical solution built inside a medically integrated specialty pharmacy at Moffitt Cancer Center: a novel scoring scorecard designed to rate oral oncology therapies by real-world accessibility. The framework pulls access variables into one view so teams can compare options and have more transparent conversations about what it may take to start therapy. It was piloted in a thoracic clinic and is expanding to additional clinics, with an eye toward adaptability across institutions and future workflow integration.
Key highlights
- Why oral oncolytics still get delayed after a “yes” decision
- A scorecard approach to make access visible at the point of prescribing
- What the score measures, including support programs and distribution restrictions
- How the 1–5 scoring system is designed for quick interpretation in clinic
- Early real-world piloting in a thoracic clinic and expansion plans
Get the full breakdown of the novel access scorecard and how it can support access-informed decisions for oral oncology therapies in the full article in Oncolytics Today.